Long-term capital for the UK's most innovative companies in life sciences, technology and sustainability.
The UK growth-stage funding gap remains acute in high-growth sectors. With government support via the Mansion House Compact and British Patient Capital programme, and aligned to UK industrial strategy and Net Zero, our growth equity strategy backs the founders building the next generation of UK champions.
Focused exposure to the highest-growth segments of the UK innovation economy — life sciences, technology and sustainability.
| Sub-Strategy | Purpose |
|---|---|
| Life Sciences | Back UK biotech, drug discovery and health innovators |
| Technology | Scale UK technology leaders across fintech, AI and advanced manufacturing |
| Sustainability | Net Zero and ESG-aligned UK growth companies |
100 years of combined experience with deep expertise in venture capital, life sciences and sustainable high-growth UK technology.
Proprietary UK growth equity opportunities sourced through deep relationships with founder communities, accelerators and early-stage VCs.
Return parameters are shared with eligible professional investors under NDA.
Significant and comprehensive co-investment opportunity across deployments.
An institutional risk-management and governance framework — independent investment committee, valuation, audit and ESG oversight — built in from day one.
Materials and detailed strategy decks are available under NDA. All enquiries are handled personally by a member of the leadership team.
Request a Conversation